RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis

Abstract

Objective

Previous studies have reported that Ras-associated domain family 1A (RASSF1A), the most commonly silenced tumor suppressor via promoter methylation, played vital roles in the development of carcinogenesis. The purpose of this meta-analysis was to determine whether RASSF1A promoter methylation increased the risk of thyroid cancer.

Methods

PubMed, Embase, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure databases were searched to obtain eligible studies. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of the associations, using Stata 12.0 software. The methodological quality of included studies was evaluated using Newcastle–Ottawa scale table. Egger’s test and Begg’s test were applied to detect publication biases. TSA 0.9 software was used to calculate the required information size and whether the result was conclusive.

Results

A total of 10 articles with 12 studies that included 422 thyroid cancer patients, identifying the association of RASSF1A promoter methylation with thyroid cancer risk, were collected in this meta-analysis. Overall, RASSF1A promoter methylation significantly increased the risk of thyroid cancer (total, OR=8.27, CI=4.38–15.62, P<0.05; Caucasian, OR=9.25, CI=3.97–21.56, P<0.05; Asian, OR=7.01, CI=2.68–18.38, P<0.05). In the subgroup analysis based on sample type, a significant association between thyroid cancer group and control group was found (normal tissue, OR=9.55, CI=4.21–21.67, P<0.05; adjacent tissue, OR=6.80, CI=2.49–18.56, P<0.05). The frequency of RASSF1A promoter methylation in follicular thyroid carcinoma was higher than in control group (OR=11.88, CI=5.80–24.32, P<0.05). In addition, the results indicated that the RASSF1A promoter methylation was correlated with papillary thyroid carcinoma in Caucasians and Asians (total, OR=8.07, CI=3.54–18.41, P<0.05; Caucasian, OR=11.35, CI=2.39–53.98, P<0.05; Asian, OR=6.67, CI=2.53–17.64, P<0.05). On the basis of the trial sequential analysis, the significant association of RASSF1A promoter methylation with thyroid cancer risk was found, and there was no need to perform further studies.

Conclusion

This meta-analysis confirms that RASSF1A promoter methylation is a risk factor for thyroid tumor.

Keywords:

• RASSF1A
• methylation
• thyroid neoplasms
• meta-analysis

Supplementary materials

Table S1 Thyroid cancer risk

Table S2 Meta-analysis table

Table S3 TNM-stage

Table S4 Distant metastasis

Table S5 Papillary thyroid carcinoma

Table S6 Follicular thyroid carcinoma

References

• SantoroAPannoneGCarosiMABRAF mutation and RASSF1A expression in thyroid carcinoma of southern ItalyJ Cell Biochem201311451174118223192464
   PubMedGoogle Scholar
• BraitMLoyoMRosenbaumECorrelation between BRAF mutation and promoter methylation of TIMP3, RARbeta2 and RASSF1A in thyroid cancerEpigenetics20127771071922694820
   PubMed Web of Science ®Google Scholar
• QuFXueWJRASSF1A methylation and its clinical roles in papillary thyroid carcinomaJ Nantong University (Medical Sciences)201232490491
   Google Scholar
• DaiYLCaiDHChenHZhangZZhangHLiJThe association of the methylation of TSHR and RASSF1A with thyroid cancerShaanxi Med J2011401114461449
   Google Scholar
• Mohammadi-aslJLarijaniBKhorgamiZQualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARbeta2 genes in papillary thyroid carcinomaMed Oncol20112841123112820535589
   PubMedGoogle Scholar
• WangXHZhangGCLiuYLSunGFNongWXYaoESThe detection of RASSF1A promoter methylation in thyroid tumor patientsShaanxi Med J200938790792
   Google Scholar
• LeeJJGeliJLarssonCGene-specific promoter hypermethylation without global hypomethylation in follicular thyroid cancerInt J Oncol200833486186918813801
   PubMed Web of Science ®Google Scholar
• NakamuraNCarneyJAJinLRASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumorsLab Invest20058591065107515980887
   PubMedGoogle Scholar
• XingMCohenYMamboEEarly occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesisCancer Res20046451664166814996725
   PubMedGoogle Scholar
• SchagdarsurenginUGimmOHoang-VuCDralleHPfeiferGPDammannRFrequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinomaCancer Res200262133698370112097277
   PubMed Web of Science ®Google Scholar

Disclosure

The authors report no conflicts of interest in this work.